Neuroscience Therapy Corp receives US approval to market pain-relief
15 May 2006
Neuroscience Therapy Corp. (OTC: NPYC) has received FDA
approval to begin marketing its electronic pain relief device the P-Stim in
the United States.
P-Stim, which the company claims has been highly
successful in treating pain in thousands of patients in Europe, is now
permitted to be marketed in the U.S. It is a miniaturized
electro-stimulation device that is placed behind the ear with adhesive. It
transmits low frequency electrical pulses via acupuncture-like needles
inserted into the ear muscles. The electrical stimulation releases
endorphins, which have an analgesic effect. The P-Stim can give continuous
pain therapy over several days.
It was stated by the National Institute of
Health: “Pain is a critical national health problem. It is the most common
reason for medical appointments, nearly 40 million visits annually, and
costs this country over $100 billion each year in health care and lost
Neuroscience Therapy is now able to enter the multi-billion dollar market
for pain releif in the U.S. and plans to begin a nationwide campaign to
President and CEO Dr. Randolph A. Turpin of Neuroscience Therapy said: “I’m
very proud of our team for enabling Neuroscience Therapy to get to this
point. We are now in an ideal position to begin making revenues in this
multi-billion dollar market.” The company claims that its product has no
known side effects, unlike many pharmaceutical pain relievers.